In vitro activities of doripenem and other carbapenems against clinically important bacteria isolated in intensive care units: Nationwide data from the SMART Programme

S. S. Jean, P. R. Hsueh, W. S. Lee, H. T. Chang, M. Y. Chou, I. S. Chen, J. H. Wang, C. F. Lin, J. M. Shyr, W. C. Ko, J. J. Wu, Y. C. Liu, W. K. Huang, L. J. Teng, C. Y. Liu

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

This nationwide surveillance of clinically important bacteria from the intensive care units (ICUs) of major teaching hospitals throughout Taiwan investigated the susceptibilities to doripenem and other comparator carbapenems from September through November 2005. Minimum inhibitory concentrations (MICs) were determined for 1,311 clinical isolates using the broth microdilution method according to Clinical and Laboratory Standards Institute (CLSI) 2005 guidelines. Doripenem showed similar (within four-fold difference of MICs) in vitro activity to meropenem for Enterobacteriaceae and probably comparable activity to meropenem against important nosocomial non-fermentative Gram-negative bacilli (NFGNBs), including Pseudomonas aeruginosa, Acinetobacter baumannii and Burkholderia cepacia. Among the four carbapenems analysed, doripenem and meropenem exhibited better in vitro activity than imipenem or ertapenem against extended-spectrum β-lactamase (ESBL)-producing Klebsiella pneumoniae and Escherichia coli isolates. However, the meropenem MIC 90 against ESBL-producing K. pneumoniae isolates was 2 μg/ml. Besides, doripenem with the MIC90 of 0.5 μg/ml to Streptococcus pneumoniae possibly suggested its potential therapeutic effect regarding community-acquired pneumonia. Because of the heavy resistance burden in Taiwan, closely monitoring the evolutionary trend of carbapenem susceptibilities against clinically important pathogens is crucial in the future.

Original languageEnglish
Pages (from-to)471-475
Number of pages5
JournalEuropean Journal of Clinical Microbiology and Infectious Diseases
Volume29
Issue number4
DOIs
Publication statusPublished - Apr 2010
Externally publishedYes

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'In vitro activities of doripenem and other carbapenems against clinically important bacteria isolated in intensive care units: Nationwide data from the SMART Programme'. Together they form a unique fingerprint.

  • Cite this